Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CPH from our risk checks.
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$18.99 |
52 Week High | CA$19.69 |
52 Week Low | CA$4.10 |
Beta | 1.24 |
11 Month Change | 56.55% |
3 Month Change | 112.18% |
1 Year Change | 378.34% |
33 Year Change | 808.61% |
5 Year Change | 1,317.16% |
Change since IPO | 413.24% |
Recent News & Updates
Recent updates
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Mar 23Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
Mar 22Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
May 14Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)
May 18Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next
Mar 20Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%
Jan 26Shareholder Returns
CPH | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 12.0% | -8.5% | -0.07% |
1Y | 378.3% | -4.5% | 12.8% |
Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned 12.8% over the past year.
Price Volatility
CPH volatility | |
---|---|
CPH Average Weekly Movement | 9.2% |
Pharmaceuticals Industry Average Movement | 10.5% |
Market Average Movement | 8.0% |
10% most volatile stocks in CA Market | 16.7% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: CPH's share price has been volatile over the past 3 months.
Volatility Over Time: CPH's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.
Cipher Pharmaceuticals Inc. Fundamentals Summary
CPH fundamental statistics | |
---|---|
Market cap | CA$485.93m |
Earnings (TTM) | CA$30.46m |
Revenue (TTM) | CA$29.86m |
16.0x
P/E Ratio16.3x
P/S RatioIs CPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CPH income statement (TTM) | |
---|---|
Revenue | US$22.16m |
Cost of Revenue | US$4.19m |
Gross Profit | US$17.97m |
Other Expenses | -US$4.64m |
Earnings | US$22.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.88 |
Gross Margin | 81.08% |
Net Profit Margin | 102.01% |
Debt/Equity Ratio | 0% |
How did CPH perform over the long term?
See historical performance and comparison